Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes

Higher serum urate levels are associated with an increased risk of diabetic kidney disease. This double blind trial investigated whether lowering serum urate with allopurinol could slow the decline in glomerular filtration rate (GFR) in patients with type 1 diabetes and early to moderate diabetic kidney disease. Participants were randomly assigned to receive allopurinol or placebo. The primary outcome was the baseline adjusted GFR after 3 years plus a 2month washout period. Results showed no clinically meaningful benefits of allopurinol on kidney outcomes, with similar GFR declines in both groups. The study concluded that serum urate reduction with allopurinol did not significantly alter kidney disease progression in this patient population.

Higher serum urate levels are associated with an increased risk of diabetic kidney disease. This double blind trial investigated whether lowering serum urate with allopurinol could slow the decline in glomerular filtration rate (GFR) in patients with type 1 diabetes and early to moderate diabetic kidney disease. Participants were randomly assigned to receive allopurinol or placebo. The primary outcome was the baseline adjusted GFR after 3 years plus a 2month washout period. Results showed no clinically meaningful benefits of allopurinol on kidney outcomes, with similar GFR declines in both groups. The study concluded that serum urate reduction with allopurinol did not significantly alter kidney disease progression in this patient population.